Published in Expert Opin Drug Metab Toxicol on August 16, 2016
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Lessons from the cancer genome. Cell (2013) 8.12
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol (2007) 4.96
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 2.97
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol (2001) 1.96
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol Lett (2002) 1.62
Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res (2009) 1.51
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol (2015) 1.42
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol (2010) 1.40
Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol (2002) 1.25
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
Impact of differential glycosylation on IgG activity. Adv Exp Med Biol (2011) 1.11
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol (2015) 1.00
Melanoma as a model tumour for immuno-oncology. Ann Oncol (2012) 0.95
Constitutive association of SHP-1 with leukocyte-associated Ig-like receptor-1 in human T cells. J Immunol (2001) 0.87
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br J Dermatol (2005) 0.83
Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol (2014) 0.82
Immunotherapy of melanoma. EJC Suppl (2013) 0.81